Edition:
India

Obseva SA (OBSV.OQ)

OBSV.OQ on NASDAQ Stock Exchange Global Select Market

9.80USD
15 Dec 2017
Change (% chg)

-- (--)
Prev Close
$9.80
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
7,965
52-wk High
$14.18
52-wk Low
$5.02

Summary

Name Age Since Current Position

Frank Verwiel

54 2016 Independent Chairman of the Board

Ernest Loumaye

64 Chief Executive Officer, Director

Timothy Adams

57 2017 Chief Financial Officer

Jean-Pierre Gotteland

52 2015 Chief Scientific Officer

Fabien de Ladonchamps

38 2016 Vice President - Finance

Ben Tan

58 2014 Vice President - Commercial & Business Development

Elke Bestel

50 2015 Chief Medical Officer and Head of Pharmacovigilance

Nanna Luneborg

41 2016 Director

Annette Clancy

63 2016 Independent Director

Barbara Duncan

52 2016 Independent Director

James Healy

52 2013 Independent Director

Edward Mathers

57 2016 Independent Director

Rafaele Tordjman

2013 Independent Director

Jacky Vonderscher

62 2013 Independent Director

Biographies

Name Description

Frank Verwiel

Dr. Frank A. G. M. Verwiel, M.D. serves as Independent Chairman of the Board of the Company. He has served as a member of our board of directors since March 2016 and has served as the chairperson of the board since December 2016. Dr. Verwiel was the President and Chief Executive Officer of Aptalis Pharma Inc. from 2005 to 2014, where he also served on the board of directors. He currently serves as a member of the board of directors of the public companies Achillion Pharmaceuticals, Inc., a pharmaceutical company, Avexis, Inc., a biotechnology company, and Bavarian Nordic A/S, a biotechnology company. Dr. Verwiel previously served on the board of directors of InterMune, Inc. from 2012 to 2014. Dr. Verwiel was also a director of the Biotechnology Industry Organisation. Dr. Verwiel received his M.D. from Erasmus University, Rotterdam, The Netherlands, and his M.B.A. from INSEAD in Fontainebleau, France. Our board of directors believes that Dr. Verwiel’s scientific acumen and his over 25 years of strategic, operational and international experience in the pharmaceutical industry provide him with the qualifications and skills to serve as a director.

Ernest Loumaye

Dr. Ernest Loumaye, M.D., Ph.D. serves as Chief Executive Officer, Director of the Company. Dr. Loumaye is a co-founder of our company and has served as our Chief Executive Officer since our inception in November 2012. Previously, Dr. Loumaye co-founded PregLem SA, a Swiss specialty biopharmaceutical company, and served as its Chief Executive Officer from 2006 until October 2012. Dr. Loumaye currently serves as the chairman of the board of directors of GenKyoTex S.A., a private Swiss pharmaceutical company. Dr. Loumaye holds a M.D. and a Ph.D. from Louvain University, with a specialization in Obstetrics and Gynaecology. Our board of directors believes that Dr. Loumaye’s leadership of our company since its inception and experience with biopharmaceutical companies prior to founding our company provide him with the qualifications and skills to serve as a director.

Timothy Adams

Mr. Timothy M. (Tim) Adams has been Chief Financial Officer of ObsEva Ltd since January 2017. From June 2014 to September 2016, Mr. Adams served as the Chief Financial Officer of Demandware, Inc. Mr. Adams served as Senior Vice President and Chief Financial Officer of athenahealth, Inc. from January 2010 to June 2014. Previously, Mr. Adams served as Chief Investment Officer of Constitution Medical Investors, Inc., a private investment firm focused on health-care-sector-related acquisitions and investments, as well as Senior Vice President of Corporate Strategy for Keystone Dental, Inc., a provider of dental health products and solutions. Earlier in his career, Mr. Adams was Chief Financial Officer at a number of other publicly traded companies. Mr. Adams began his career in public accounting at PricewaterhouseCoopers LLP, formerly Price Waterhouse, and is a Certified Public Accountant. Mr. Adams has served as a member of the board of directors of ABILITY Network, a private healthcare technology company, since November 2014. Mr. Adams has served as a member of the board of directors of Model N, a public revenue management solutions company, since December 2016. Mr. Adams obtained a B.S. from Murray State University and an MBA degree from Boston University.

Jean-Pierre Gotteland

Dr. Jean-Pierre Gotteland, Ph.D., serves as Chief Scientific Officer of ObsEva Ltd., since September 2015. From May 2007 to August 2015, Dr. Gotteland worked at PregLem SA, initially as the Vice President of Non-Clinical Development and CMC from 2007 to 2012 and as the Chief Development Officer from January 2012 to August 2015. From 1998 to 2007, Dr. Gotteland held several research and development positions at Serono (subsequently Merck Serono). From 1991 to 1998, Dr. Gotteland served as medicinal chemistry group leader at Pierre Pabre Meclicament. Dr. Gotteland holds a Ph.D. in Organic Chemistry from the University Claude Bernard and an Engineering Diploma from Ecole Superieure de Chimie Industrielle.

Fabien de Ladonchamps

Mr. Fabien Lefebvre de Ladonchamps serves as Vice President - Finance of the Company. He has served as our Vice President of Finance since January 2016 and previously served as our Finance Director from October 2013 to December 2015. Prior to joining our company, Mr. de Ladonchamps worked at Addex Therapeutics, initially as Chief Accountant from 2008 to 2009 and then as Group Financial Controller from 2010 to September 2013. Mr. de Ladonchamps holds a French degree in Finance and Accounting from the Lyon III University in Lyon, France.

Ben Tan

Mr. Ben T.G. Tan has served as Vice President - Commercial & Business Development of the Company, since September 2014. Prior to joining our company, Mr. Tan worked at Evolva SA, as Director, Business Development Pharmaceuticals from April 2012 to March 2014. Prior to joining Evolva SA, Mr. Tan worked at Novartis as Global Program Strategic Director, Cardiovascular and Metabolic Diseases from 2008 to 2011. Prior to joining Novartis, Mr. Tan worked at Speedel as Head of Business Development & Licensing from 2001 to 2008. Prior to joining Speedel, Mr. Tan worked at Devgen, as Executive Vice President of Business from 2000 to 2001. Prior to joining Devgen, Mr. Tan worked at Organon, as Global Head of Licensing from 1997 to 2000. Prior to joining Organon, Mr. Tan worked at Roche, as Global Business Leader/International Product Manager from 1994 to 1997, and at Roche Netherlands, as Head of Medical Marketing from 1990 to 1993. Mr. Tan holds an M.S. from the Vrije Universiteit Amsterdam.

Elke Bestel

Dr. Elke Bestel serves as Chief Medical Officer and Head of Pharmacovigilance of the Company, since September 2015. Prior to joining our company, Dr. Bestel worked at PregLem SA, initially as a Global Project Director from 2008 to 2009, then as the Vice President Clinical Operations from 2009 to August 2012 and finally as the Chief Medical Officer from September 2012 to August 2015. Dr. Bestel studied at the Georg-August University Medical School of Göttingen, Germany and the Ludwig-Maximilian University Medical School of Munich, Germany. Dr. Bestel holds an M.D. from the University of Göttingen.

Nanna Luneborg

Dr. Nanna Luneborg serves as Director of the Company. She has served as a member of our board of directors since April 2016. Since March 2012, Dr. Lüneborg has been employed as a principal of Novo A/S, a Danish limited liability company that manages investments and financial assets. Prior to joining Novo A/S, Dr. Lüneborg was an associate at Apposite Capital from July 2008 to January 2012 and previously held various roles from May 2005 to July 2007 with Cancer Research UK. Dr. Lüneborg was nominated to our board of directors by Novo A/S. Dr. Lüneborg holds a Ph.D. in Neuroscience from University College London, an MBA with distinction from University of Cambridge, and a 1st class BA from University of Oxford. Dr. Lüneborg is currently on the board of directors of several private companies. Our board of directors believes that Dr. Lüneborg’s experience in the pharmaceutical industry and investing in life sciences companies, as well as her medical and scientific background, provide her with the qualifications and skills to serve as a director.

Annette Clancy

Ms. Annette Clancy serves as Independent Director of the Company. She has served as a member of our board of directors since November 2013 and served as our chairperson from November 2013 to December 2016. Since 2009, Ms. Clancy has been a senior advisor at Frazier Healthcare Ventures, a U.S.-based healthcare venture capital firm. Prior to joining Frazier Healthcare Ventures, Ms. Clancy held various positions at GlaxoSmithKline, a global healthcare company. Ms. Clancy is currently on the board of directors of Swedish Orphan Biovitrum AB, a public biopharmaceutical company, as well as several private companies. Ms. Clancy holds a B.Sc. in Pharmacology from Bath University and a series of American Management Association diplomas in finance and marketing. Our board of directors believes that Ms. Clancy’s over 30 years of experience in the pharmaceutical and biopharmaceutical industries provide her with the qualifications and skills to serve as a director.

Barbara Duncan

Ms. Barbara G. Duncan serves as Independent Director of the Company. She has served as a member of our board of directors since December 2016. From May 2009 through June 2016, Ms. Duncan served as the Chief Financial Officer of Intercept Pharmaceuticals, Inc., a biopharmaceutical company. Prior to joining Intercept Pharmaceuticals, Inc., Ms. Duncan served as the Chief Financial Officer and then Chief Executive Officer of DOV Pharmaceutical, Inc., or DOV, from 2001 to April 2009. Prior to joining DOV, Ms. Duncan served as a vice president of Lehman Brothers Inc. in its corporate finance division from August 1998 to August 2001. From September 1994 to August 1998, Ms. Duncan was an associate and director at SBC Warburg Dillon Read, Inc. in its corporate finance group. Ms. Duncan serves on the board of directors of Aevi Genomic Medicines, Inc., a biopharmaceutical company, and Adaptimmune Therapeutics plc, a biopharmaceutical company, and Innoviva, Inc., a biopharmaceutical company, as well as two private companies. Ms. Duncan received her B.S. from Louisiana State University in 1985 and her M.B.A. from the Wharton School, University of Pennsylvania, in 1994. Our board of directors believes that Ms. Duncan’s expertise with public and financial accounting matters, as well as her experience in the pharmaceutical industry, provide her with the qualifications and skills to serve as a director.

James Healy

Dr. James I. Healy, M.D., Ph.D. serves as Independent Director of the Company. He has served as a member of our board of directors since August 2013. Dr. Healy has been a General Partner of Sofinnova Ventures, a venture capital firm, since June 2000. Prior to June 2000, Dr. Healy held various positions at Sanderling Ventures, Bayer Healthcare Pharmaceuticals (as successor to Miles Laboratories) and ISTA Pharmaceuticals, Inc. Dr. Healy is currently on the board of directors of the public companies Ascendis Pharma A/S, a clinical-stage pharmaceutical company, Auris Medical Holding AG, a biopharmaceutical company, Coherus BioSciences, Inc., a biologics platform company, Amarin Corporation PLC, a biopharmaceutical company, Edge Therapeutics, Inc., a biotechnology company, and Natera, Inc., a genetic testing company, as well as several private companies. Previously, he served as a board member of InterMune, Inc., Anthera Pharmaceuticals, Inc., Durata Therapeutics, Inc., CoTherix, Inc., Hyperion Therapeutics, Inc. and KaloBios Pharmaceuticals, Inc. Dr. Healy was nominated to our board of directors by Sofinnova Ventures. Dr. Healy holds an M.D. and a Ph.D. in Immunology from the Stanford School of Medicine and holds a B.A. in Molecular Biology and a B.A. in Scandinavian Studies from the University of California at Berkeley. Our board of directors believes that Dr. Healy’s experience in the pharmaceutical industry and investing in life sciences companies, as well as his medical and scientific background, provide him with the qualifications and skills to serve as a director.

Edward Mathers

Mr. Edward Mathers serves as Independent Director of the Company. He has served as a member of our board of directors since February 2016. Since August 2008, Mr. Mathers has been a Partner at New Enterprise Associates, Inc., or NEA, a private venture capital firm focusing on technology and healthcare investments. Mr. Mathers serves on the board of directors of Envisia Therapeutics, Inc., a biopharmaceutical company, Liquidia Technologies, a biotechnology company, Ra Pharmaceuticals, Inc., a pharmaceutical company, Rhythm Pharmaceuticals, a pharmaceutical company, Lumos Pharma, a biotechnology company, Mirna Therapeutics, Inc., a pharmaceutical company, as well as several private companies. From 2002 to 2008, Mr. Mathers served as Executive Vice President, Corporate Development and Venture at MedImmune, Inc., or MedImmune, and led its venture capital subsidiary, MedImmune Ventures, Inc. Before joining MedImmune in 2002, he was Vice President, Marketing and Corporate Licensing and Acquisitions at Inhale Therapeutic Systems. Previously, Mr. Mathers spent 15 years at Glaxo Wellcome, Inc. where he held various sales and marketing positions. Mr. Mathers was nominated to our board of directors by NEA. Mr. Mathers holds a B.S. in Chemistry from North Carolina State University. Our board of directors believes that Mr. Mathers’s experience with the healthcare and pharmaceutical industries and his broad management experience provide him with the qualifications and skills to serve as a director.

Rafaele Tordjman

Dr. Rafaele Tordjman serves as Independent Director of the Company. She has served as a member of our board of directors since August 2013. Dr. Tordjman joined the French venture capital firm Sofinnova Partners in 2001 and is a Managing Partner specializing in life sciences investments. Dr. Tordjman serves on the board of directors of the public company Ascendis Pharma A/S, a clinical-stage pharmaceutical company. Dr. Tordjman has also served on the boards of directors at several life sciences companies including, DBV Technologies SA, a French publicly traded company specializing in allergy therapies, Flexion Therapeutics, Inc., a publicly traded company specializing in clinical-stage pharmaceuticals, as well as a private company, and Preglem, a company that specialized in reproductive female medicine. Previously, Dr. Tordjman was a research scientist at the Institut National de la Santé et de la Recherche Médicale (INSERM) in Cochin Hospital, Paris, France. Dr. Tordjman has also practiced as a medical doctor, specializing in clinical hematology and internal medicine. Dr. Tordjman was nominated to our board of directors by Sofinnova Partners. Dr. Tordjman received an M.D. and completed a fellowship in hematology and internal medicine at the Paris University Hospitals. She received a Ph.D. in hematopoiesis and angiogenesis from and completed a post-doctoral fellowship in immunology at the University of Paris VII. Our board of directors believes that Dr. Tordjman’s experience in the pharmaceutical industry and investing in life sciences companies, as well as her medical and scientific background, provide her with the qualifications and skills to serve as a director.

Jacky Vonderscher

Dr. Jacky Vonderscher, Ph.D. serves as Independent Director of the Company. He has served as a member of our board of directors since October 2013. Since September 2013, Dr. Vonderscher has served as the Chief Executive Officer of Vonderscher & Co GmbH, a consultancy company, and since January 2014, Dr. Vonderscher has served as the President of ENYO Pharma, a biopharmaceutical company. Dr. Vonderscher has also served as the Chief Executive Officer of ENYO Pharma since July 2016. Prior to joining ENYO Pharma, Dr. Vonderscher served as a Senior Vice President of Hoffmann-La-Roche Ltd from 2008 to December 2013. From 1979 to 2008, Dr. Vonderscher held a variety of senior positions at Novartis Pharma AG. Dr. Vonderscher also serves on the boards of directors of several private companies. Dr. Vonderscher holds an engineering degree in Biological Chemistry from the National Institute of Applied Sciences (INSA-Lyon, France) and a Ph.D. in Biochemistry from the University of Geneva. Our board of directors believes that Dr. Vonderscher’s experience in the pharmaceutical industry, as well as his scientific background, provide him with the qualifications and skills to serve as a director.